JP2018503357A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018503357A5 JP2018503357A5 JP2017526547A JP2017526547A JP2018503357A5 JP 2018503357 A5 JP2018503357 A5 JP 2018503357A5 JP 2017526547 A JP2017526547 A JP 2017526547A JP 2017526547 A JP2017526547 A JP 2017526547A JP 2018503357 A5 JP2018503357 A5 JP 2018503357A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- diseases
- tfr
- modification
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 15
- 230000004048 modification Effects 0.000 claims 15
- 238000012986 modification Methods 0.000 claims 15
- 102000007238 Transferrin Receptors Human genes 0.000 claims 13
- 108010033576 Transferrin Receptors Proteins 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 12
- 239000012636 effector Substances 0.000 claims 8
- 150000001413 amino acids Chemical group 0.000 claims 7
- 210000003169 central nervous system Anatomy 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 230000024203 complement activation Effects 0.000 claims 5
- 230000013595 glycosylation Effects 0.000 claims 5
- 238000006206 glycosylation reaction Methods 0.000 claims 5
- 201000001119 neuropathy Diseases 0.000 claims 5
- 230000007823 neuropathy Effects 0.000 claims 5
- 208000033808 peripheral neuropathy Diseases 0.000 claims 5
- 210000001995 reticulocyte Anatomy 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 102100021257 Beta-secretase 1 Human genes 0.000 claims 3
- 101710150192 Beta-secretase 1 Proteins 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 208000015439 Lysosomal storage disease Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000012902 Nervous system disease Diseases 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 206010002022 amyloidosis Diseases 0.000 claims 3
- 230000003542 behavioural effect Effects 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 208000030533 eye disease Diseases 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 208000028867 ischemia Diseases 0.000 claims 3
- 230000000813 microbial effect Effects 0.000 claims 3
- 230000004770 neurodegeneration Effects 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 230000002981 neuropathic effect Effects 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 claims 2
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 claims 2
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 claims 2
- 102100029470 Apolipoprotein E Human genes 0.000 claims 2
- 101710095339 Apolipoprotein E Proteins 0.000 claims 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 102000001301 EGF receptor Human genes 0.000 claims 2
- 108060006698 EGF receptor Proteins 0.000 claims 2
- 102000003951 Erythropoietin Human genes 0.000 claims 2
- 108090000394 Erythropoietin Proteins 0.000 claims 2
- 102000009109 Fc receptors Human genes 0.000 claims 2
- 108010087819 Fc receptors Proteins 0.000 claims 2
- 101000941879 Homo sapiens Leucine-rich repeat serine/threonine-protein kinase 2 Proteins 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 claims 2
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 claims 2
- 241000288906 Primates Species 0.000 claims 2
- 102000029797 Prion Human genes 0.000 claims 2
- 108091000054 Prion Proteins 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- 102100022205 Tumor necrosis factor receptor superfamily member 21 Human genes 0.000 claims 2
- 101710187751 Tumor necrosis factor receptor superfamily member 21 Proteins 0.000 claims 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 210000003743 erythrocyte Anatomy 0.000 claims 2
- 229940105423 erythropoietin Drugs 0.000 claims 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 2
- 230000014759 maintenance of location Effects 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 2
- 238000011287 therapeutic dose Methods 0.000 claims 2
- 102100026882 Alpha-synuclein Human genes 0.000 claims 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 102000004018 Caspase 6 Human genes 0.000 claims 1
- 108090000425 Caspase 6 Proteins 0.000 claims 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 claims 1
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 claims 1
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 claims 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 1
- 108010036933 Presenilin-1 Proteins 0.000 claims 1
- 102000012412 Presenilin-1 Human genes 0.000 claims 1
- 108010036908 Presenilin-2 Proteins 0.000 claims 1
- 102000012419 Presenilin-2 Human genes 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 229930003779 Vitamin B12 Natural products 0.000 claims 1
- 229930003268 Vitamin C Natural products 0.000 claims 1
- 108090000185 alpha-Synuclein Proteins 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 125000000837 carbohydrate group Chemical group 0.000 claims 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000011161 development Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 229960000304 folic acid Drugs 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- -1 huntingtin Proteins 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 102000045222 parkin Human genes 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 239000013589 supplement Substances 0.000 claims 1
- 102000013498 tau Proteins Human genes 0.000 claims 1
- 108010026424 tau Proteins Proteins 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
- 235000019163 vitamin B12 Nutrition 0.000 claims 1
- 239000011715 vitamin B12 Substances 0.000 claims 1
- 235000019154 vitamin C Nutrition 0.000 claims 1
- 239000011718 vitamin C Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462081827P | 2014-11-19 | 2014-11-19 | |
| US62/081,827 | 2014-11-19 | ||
| PCT/US2015/061405 WO2016081643A1 (en) | 2014-11-19 | 2015-11-18 | Anti-transferrin receptor antibodies and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020173079A Division JP2021035365A (ja) | 2014-11-19 | 2020-10-14 | 抗トランスフェリン受容体抗体及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018503357A JP2018503357A (ja) | 2018-02-08 |
| JP2018503357A5 true JP2018503357A5 (enExample) | 2018-12-27 |
| JP6779876B2 JP6779876B2 (ja) | 2020-11-04 |
Family
ID=54780465
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017526547A Active JP6779876B2 (ja) | 2014-11-19 | 2015-11-18 | 抗トランスフェリン受容体抗体及びその使用方法 |
| JP2020173079A Withdrawn JP2021035365A (ja) | 2014-11-19 | 2020-10-14 | 抗トランスフェリン受容体抗体及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020173079A Withdrawn JP2021035365A (ja) | 2014-11-19 | 2020-10-14 | 抗トランスフェリン受容体抗体及びその使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10508151B2 (enExample) |
| EP (1) | EP3221362B1 (enExample) |
| JP (2) | JP6779876B2 (enExample) |
| CN (1) | CN107001473B (enExample) |
| WO (1) | WO2016081643A1 (enExample) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013033734A1 (en) | 2011-09-02 | 2013-03-07 | The Trustees Of Columbia University In The City Of New York | Diagnosis and Treatment of Cancer Expressing ILT3 or ILT3 Ligand |
| EP3594240B1 (en) * | 2013-05-20 | 2023-12-06 | F. Hoffmann-La Roche AG | Anti-transferrin receptor antibodies and methods of use |
| WO2016081640A1 (en) | 2014-11-19 | 2016-05-26 | Genentech, Inc. | Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use |
| WO2017015227A1 (en) | 2015-07-17 | 2017-01-26 | The Trustees Of Columbia University In The City Of New York | Methods of treating cd166-expressing cancer |
| US10537633B2 (en) | 2016-03-04 | 2020-01-21 | Jn Biosciences Llc | Antibodies to TIGIT |
| JP2019513371A (ja) | 2016-04-01 | 2019-05-30 | アビディティー バイオサイエンシーズ エルエルシー | 核酸ポリペプチド組成物とその使用 |
| EP3494216B1 (en) * | 2016-08-06 | 2025-10-15 | Ossianix, Inc. | In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use |
| CA3297793A1 (en) | 2016-12-26 | 2026-03-02 | Kagoshima University | Antibody which binds to myelin oligodendrocyte glycoprotein |
| CN110506055A (zh) | 2017-02-17 | 2019-11-26 | 戴纳立制药公司 | 工程改造的转铁蛋白受体结合多肽 |
| US10143187B2 (en) | 2017-02-17 | 2018-12-04 | Denali Therapeutics Inc. | Transferrin receptor transgenic models |
| WO2018152285A1 (en) * | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Transferrin receptor transgenic models |
| US10457717B2 (en) | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
| CA3053381A1 (en) * | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Engineered polypeptides |
| EP3665194A4 (en) * | 2017-08-10 | 2021-07-07 | Denali Therapeutics Inc. | AFFINITY BASED METHODS OF USING TRANSFERRIN RECEPTOR BINDING PROTEINS |
| IL253984A0 (en) * | 2017-08-14 | 2017-09-28 | Yeda Res & Dev | Immunotherapy against aranviruses that bind through transferrin receptor 1 (tfr1 |
| US20190100587A1 (en) * | 2017-10-02 | 2019-04-04 | Covagen Ag | IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS |
| CR20200129A (es) | 2017-10-02 | 2020-08-22 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas |
| WO2019094608A1 (en) | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Anti-bace1 antibodies and methods of use thereof |
| TW201934573A (zh) * | 2018-01-10 | 2019-09-01 | 美商戴納立製藥公司 | 轉鐵蛋白受體結合性多肽及其用途 |
| US12258597B2 (en) | 2018-02-07 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for therapeutic protein delivery |
| WO2019243502A1 (en) | 2018-06-21 | 2019-12-26 | Novo Nordisk A/S | Novel compounds for treatment of obesity |
| TWI857959B (zh) | 2018-06-26 | 2024-10-11 | 日商協和麒麟股份有限公司 | 與細胞黏著分子3 結合之抗體 |
| JP7397444B2 (ja) | 2018-06-26 | 2023-12-13 | 協和キリン株式会社 | コンドロイチン硫酸プロテオグリカン－５に結合する抗体 |
| CN109022389A (zh) * | 2018-07-19 | 2018-12-18 | 陕西慧康生物科技有限责任公司 | 一种大肠杆菌表达人艾杜糖醛酸-2-硫酸酯酶的生产方法 |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| KR20210086601A (ko) * | 2018-08-02 | 2021-07-08 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 프리드라이히 운동실조를 치료하기 위한 그의 용도 |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| EP3830130A4 (en) * | 2018-08-02 | 2022-05-18 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating centronuclear myopathy |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2020056327A1 (en) | 2018-09-14 | 2020-03-19 | Ossianix, Inc. | Tfr-specific binding moieties and transcytosis method to select vnars that cross cellular barriers |
| CN113226283A (zh) | 2018-10-04 | 2021-08-06 | 罗切斯特大学 | 通过操纵血浆重量摩尔渗透压浓度改善淋巴递送 |
| CN109336973B (zh) * | 2018-10-11 | 2021-08-24 | 中国科学院昆明动物研究所 | 抗转铁蛋白抗体及其用途 |
| AR117453A1 (es) * | 2018-12-20 | 2021-08-04 | Genentech Inc | Fc de anticuerpos modificados y métodos para utilizarlas |
| IL312067B2 (en) | 2018-12-21 | 2025-08-01 | Avidity Biosciences Inc | Anti-transferrin receptor antibodies and uses thereof |
| WO2020138487A1 (ja) * | 2018-12-28 | 2020-07-02 | 協和キリン株式会社 | ＴｆＲに結合するバイスペシフィック抗体 |
| EP4026560A4 (en) * | 2019-09-04 | 2023-10-25 | Perseus Proteomics Inc. | THERAPEUTIC AGENT AGAINST POLYCYTHEMIA |
| WO2021076931A1 (en) * | 2019-10-18 | 2021-04-22 | Centivax, Inc. | Antibodies and uses thereof |
| EP4069745A4 (en) * | 2019-11-06 | 2024-05-29 | The Regents Of The University Of California | COMPOSITIONS AND METHODS FOR TRANSFERRIN RECEPTOR 1 TARGETING |
| PH12022551598A1 (en) | 2019-12-23 | 2023-11-20 | Denali Therapeutics Inc | Progranulin variants |
| CA3163283A1 (en) * | 2020-01-10 | 2021-07-15 | Romesh R. Subramanian | Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health |
| JP7780691B2 (ja) * | 2020-01-10 | 2025-12-05 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
| CN115427059A (zh) * | 2020-01-31 | 2022-12-02 | 达因疗法公司 | 抗转铁蛋白受体（tfr）抗体及其用途 |
| US20230103793A1 (en) * | 2020-01-31 | 2023-04-06 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (tfr) antibody and uses thereof |
| WO2021188390A1 (en) | 2020-03-19 | 2021-09-23 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
| SI4126066T1 (sl) | 2020-03-27 | 2026-04-30 | Avidity Biosciences, Inc. | Sestavki in postopki zdravljenja mišične distrofije |
| CN121754667A (zh) * | 2020-04-08 | 2026-03-31 | 阿里亚达治疗公司 | 用于血脑屏障递送的组合物和方法 |
| AU2021278819A1 (en) * | 2020-05-05 | 2022-11-24 | Annexon, Inc. | Compositions and methods for treating epilepsy |
| MX2022015157A (es) | 2020-06-02 | 2023-01-16 | Arcus Biosciences Inc | Anticuerpos para tigit. |
| PE20231104A1 (es) | 2020-07-21 | 2023-07-19 | Genentech Inc | Inductores quimicos de degradacion conjugados con anticuerpo de brm y metodos de estos |
| CA3193273A1 (en) * | 2020-08-27 | 2022-03-03 | Enosi Therapeutics Corporation | Methods and compositions to treat autoimmune diseases and cancer |
| CA3202832A1 (en) | 2020-12-31 | 2022-07-07 | Romesh R. Subramanian | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| CA3226301A1 (en) * | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| JP2024525608A (ja) | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体および製剤 |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| WO2023034409A1 (en) | 2021-09-01 | 2023-03-09 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof |
| CN118265544A (zh) | 2021-09-16 | 2024-06-28 | 艾维迪提生物科学公司 | 治疗面肩肱型肌营养不良的组合物和方法 |
| US11939391B2 (en) * | 2021-12-06 | 2024-03-26 | MedAbome, Inc. | Anti-TfR1 antibody MAb11-22.1 conjugates for cancer treatment |
| AR128330A1 (es) | 2022-01-26 | 2024-04-17 | Genentech Inc | Inductores químicos de degradación conjugados con anticuerpo y métodos de estos |
| AR128331A1 (es) | 2022-01-26 | 2024-04-17 | Genentech Inc | Inductores químicos de degradación conjugados con anticuerpos y métodos de estos |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| CA3263388A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | VIRAL PARTICLES RETRIBUTED TO TRANSFERRIN RECEPTOR 1 |
| IL317261A (en) | 2022-07-29 | 2025-01-01 | Regeneron Pharma | Non-human animals containing a modified transferrin receptor locus |
| US20260116990A1 (en) | 2022-11-23 | 2026-04-30 | Key2Brain Ab | Vhh antibodies and uses thereof |
| KR20250111123A (ko) | 2022-11-23 | 2025-07-22 | 키2브레인 에이비 | Vhh 항체 및 이의 용도 |
| WO2024187057A2 (en) * | 2023-03-08 | 2024-09-12 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof |
| AU2024299328A1 (en) | 2023-07-21 | 2026-01-22 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
| WO2025085352A1 (en) * | 2023-10-18 | 2025-04-24 | Eli Lilly And Company | Transferrin receptor binding proteins and uses thereof |
| WO2025160275A1 (en) | 2024-01-24 | 2025-07-31 | Arrowhead Pharmaceuticals, Inc. | Anti-transferrin receptor antibodies, conjugates thereof, and uses thereof |
| WO2026068519A1 (en) * | 2024-09-24 | 2026-04-02 | Bioarctic Ab | Ph sensitive binding molecule |
| WO2026068532A1 (en) * | 2024-09-24 | 2026-04-02 | Bioarctic Ab | Bispecific binding molecule |
| WO2026076250A1 (en) | 2024-10-03 | 2026-04-09 | Genentech, Inc. | Lipid nanoparticles for delivery to the cns from systemic administration |
Family Cites Families (137)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| JPS633262A (ja) | 1986-06-24 | 1988-01-08 | Toshiba Corp | 網状赤血球の分析方法及び装置 |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5672683A (en) | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| JPH07509444A (ja) | 1991-11-26 | 1995-10-19 | アルカーメス・インコーポレーテツド | トランスフェリンセレプター特異的抗体−神経薬又は診断薬複合体の製造法 |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| WO1993016177A1 (en) | 1992-02-11 | 1993-08-19 | Cell Genesys, Inc. | Homogenotization of gene-targeting events |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| ATE191853T1 (de) | 1992-07-27 | 2000-05-15 | Us Health | Zielgerichte liposome zur blut-hirne schranke |
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| ES2244066T3 (es) | 1997-06-24 | 2005-12-01 | Genentech, Inc. | Procedimiento y composiciones de glicoproteinas galactosiladas. |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| ES2248127T3 (es) | 1999-10-04 | 2006-03-16 | Medicago Inc. | Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno. |
| EP1229125A4 (en) | 1999-10-19 | 2005-06-01 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING A POLYPEPTIDE |
| EP1240319A1 (en) | 1999-12-15 | 2002-09-18 | Genentech, Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| AU767394C (en) | 1999-12-29 | 2005-04-21 | Immunogen, Inc. | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
| DE1257584T1 (de) | 2000-02-24 | 2003-05-28 | Lilly Co Eli | Humanisierte antikörper, die amyloid beta peptid demarkieren |
| JP2003531588A (ja) | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
| CA2414772C (en) | 2000-07-07 | 2011-06-28 | Jan Naslund | Prevention and treatment of alzheimer's disease |
| CA2953239A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| CA2430013C (en) | 2000-11-30 | 2011-11-22 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
| PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| NZ571596A (en) | 2001-08-03 | 2010-11-26 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| CA2451998A1 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | Anti-a.beta. antibodies |
| WO2003016467A2 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass |
| CA2463879C (en) | 2001-10-25 | 2012-12-04 | Genentech, Inc. | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
| BR0309145A (pt) | 2002-04-09 | 2005-02-01 | Kyowa Hakko Kogyo Kk | Células das quais o genoma é modificado |
| EP1500400A4 (en) | 2002-04-09 | 2006-10-11 | Kyowa Hakko Kogyo Kk | MEDICAMENT WITH ANTIBODY COMPOSITION |
| CA2481925A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for patients having human fc.gamma.riiia |
| EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING ANTIBODY COMPOSITION |
| CA2481658A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to fcy receptor iiia |
| CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
| WO2004029629A1 (en) | 2002-09-27 | 2004-04-08 | Janssen Pharmaceutica N.V. | N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses |
| US20040146512A1 (en) | 2002-10-09 | 2004-07-29 | Arnon Rosenthal | Methods of treating Alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US20050142141A1 (en) | 2002-11-27 | 2005-06-30 | Pardridge William M. | Delivery of enzymes to the brain |
| TWI335821B (en) | 2002-12-16 | 2011-01-11 | Genentech Inc | Immunoglobulin variants and uses thereof |
| WO2004065416A2 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| EA200501524A1 (ru) | 2003-03-28 | 2006-06-30 | Сентокор, Инк. | Антитела против амилоида, композиции, способы и применения |
| TWI306458B (en) | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
| JP4794301B2 (ja) | 2003-06-11 | 2011-10-19 | 中外製薬株式会社 | 抗体の製造方法 |
| JPWO2005035586A1 (ja) | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | 融合蛋白質組成物 |
| JPWO2005035778A1 (ja) | 2003-10-09 | 2006-12-21 | 協和醗酵工業株式会社 | α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法 |
| US9296820B2 (en) | 2003-11-05 | 2016-03-29 | Roche Glycart Ag | Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function |
| EP2478912B1 (en) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
| EP1740615B1 (en) | 2004-03-31 | 2014-11-05 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| PT1737891E (pt) | 2004-04-13 | 2013-04-16 | Hoffmann La Roche | Anticorpos anti p-selectina |
| PT1740616E (pt) | 2004-04-30 | 2012-03-23 | Inst Nat Sante Rech Med | Anticorpo anti-rtf |
| MX2007000998A (es) | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| WO2006039470A2 (en) | 2004-09-29 | 2006-04-13 | Centocor, Inc. | Anti- amyloid antibodies, compositions, methods and uses |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US7625560B2 (en) | 2004-12-15 | 2009-12-01 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| EP1838348B1 (en) | 2004-12-15 | 2013-06-26 | Janssen Alzheimer Immunotherapy | Humanized amyloid beta antibodies for use in improving cognition |
| CA2589017A1 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Amyloid beta antibodies for use in improving cognition |
| ES2259270B1 (es) | 2005-03-09 | 2007-11-01 | Consejo Superior De Investigaciones Cientificas | Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal. |
| US8053569B2 (en) | 2005-10-07 | 2011-11-08 | Armagen Technologies, Inc. | Nucleic acids encoding and methods of producing fusion proteins |
| ES2577292T3 (es) | 2005-11-07 | 2016-07-14 | Genentech, Inc. | Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso |
| EP1973951A2 (en) | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| EP1959996A2 (en) | 2005-12-12 | 2008-08-27 | AC Immune S.A. | Monoclonal antibody |
| TW200812616A (en) | 2006-05-09 | 2008-03-16 | Genentech Inc | Binding polypeptides with optimized scaffolds |
| EP2046833B9 (en) | 2006-07-14 | 2014-02-19 | AC Immune S.A. | Humanized antibody against amyloid beta |
| WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| ES2529174T3 (es) | 2007-06-12 | 2015-02-17 | Ac Immune S.A. | Anticuerpos humanizados para amiloide beta |
| NZ581835A (en) | 2007-06-12 | 2012-09-28 | Ac Immune Sa | Monoclonal anti beta amyloid antibody |
| WO2009027105A2 (en) | 2007-08-31 | 2009-03-05 | Neurimmune Therapeutics Ag | Method of providing patient specific immune response in amyloidoses and protein aggregation disorders |
| JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 |
| CA2818173C (en) | 2010-11-30 | 2022-05-03 | Genentech, Inc. | Low affinity blood brain barrier receptor antibodies and uses therefor |
| ES2692268T5 (en) | 2011-03-29 | 2025-02-26 | Roche Glycart Ag | Antibody fc variants |
| WO2013177062A2 (en) * | 2012-05-21 | 2013-11-28 | Genentech, Inc. | Methods for improving safety of blood-brain barrier transport |
| EP3594240B1 (en) * | 2013-05-20 | 2023-12-06 | F. Hoffmann-La Roche AG | Anti-transferrin receptor antibodies and methods of use |
-
2015
- 2015-11-18 US US15/525,832 patent/US10508151B2/en active Active
- 2015-11-18 JP JP2017526547A patent/JP6779876B2/ja active Active
- 2015-11-18 WO PCT/US2015/061405 patent/WO2016081643A1/en not_active Ceased
- 2015-11-18 CN CN201580062928.5A patent/CN107001473B/zh active Active
- 2015-11-18 EP EP15804652.4A patent/EP3221362B1/en active Active
-
2019
- 2019-10-31 US US16/670,104 patent/US11098129B2/en active Active
-
2020
- 2020-10-14 JP JP2020173079A patent/JP2021035365A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018503357A5 (enExample) | ||
| JP2016526878A5 (enExample) | ||
| JP2022141689A (ja) | Ｔａｕ結合抗体 | |
| CN111788221B (zh) | 具有与FcRn增强的结合及延长的半衰期的Fc变体 | |
| JP2018505652A5 (enExample) | ||
| JP7626416B2 (ja) | 神経変性疾患または神経炎症性疾患におけるグリア細胞活性化の早期検出方法 | |
| CA3111569A1 (en) | Anti-trem-2 agonist antibodies | |
| RU2015143886A (ru) | Антитела к тау и способы применения | |
| IL266911B2 (en) | Anti-tau antibodies and uses thereof in treating tauopathy, retaining or increasing cognitive memory capacity or slowing memory loss | |
| TW201643197A (zh) | 針對ｔａｕ之抗體及其用途 | |
| BR112019016490A2 (pt) | anticorpo humanizado para tratar ou prevenir distúrbios cognitivos, processo para produzir o mesmo e agente para tratar ou prevenir distúrbios cognitivos com o uso do mesmo | |
| JP2016525502A5 (enExample) | ||
| CN107922499A (zh) | 抗EphA4抗体 | |
| CN115697393A (zh) | 抗PHF-tau抗体及其用途 | |
| BR112020021855A2 (pt) | anticorpo antirrepetição de dipeptídeo (dpr) (poli-ga) derivado de humanos | |
| CN115175932B (zh) | 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体 | |
| JP2022509372A (ja) | 血液脳関門輸送の促進のためのヒト化され安定化されたｆｃ５バリアント | |
| TW202340249A (zh) | 生物活性降低之抗體變體 | |
| CN112041346A (zh) | 用于与抗pd-1抗体组合的抗cd137抗体 | |
| DE102019121022A1 (de) | Rekrutierungsagens, das zusätzlich ein MHC-Molekül bindet | |
| WO2025253337A2 (en) | Monospecific and bispecific tau binding proteins and compositions thereof | |
| JP2011041475A (ja) | 抗体製造方法 | |
| HK40108969A (zh) | 生物学活性降低的抗体变体 | |
| KR20260058849A (ko) | 항-tslp 항체 작제물 및 이의 용도 | |
| HK40060684B (zh) | 抗epha4抗体 |